16
Aug
2016
Tag: commercialization
6
Jul
2016
Bionest
Collective Wisdom Around Oncology – Comments on ASCO 2016
The Bionest Oncology team spent a jam packed and exciting five days at ASCO 2016 earlier this month in Chicago. More than 30,000 oncology professionals gathered from all around the world to discuss the latest data and innovations in oncology, and it did not disappoint. The theme of ASCO this year was Collective Wisdom, which...
3
Jun
2016
Bionest
Some Thoughts on the Latest Immuno-oncology Approval
On May 18, the U.S. Food and Drug Administration approved the latest immunotherapeutic drug, atezolizumab (Tecentriq), from Roche’s California division, Genentech. The drug, a PD-L1 inhibitor, is the first product in its class to gain approval for a common form of bladder cancer, urothelial carcinoma — specifically for patients with advanced disease or those who...
6
Apr
2016
Bionest
“Beyond the Pill” — Part Two: Value-Added Services Offer Benefit to Multiple Audiences
In our first “Beyond the Pill” post, we discussed the increasing move towards patient-centric programs that go past an actual prescription to help build relationships with patients and physicians and facilitate the provision of a number of related services to improve compliance and treatment outcomes and keep patients on drug long-term. The benefit of such...
31
Mar
2016
Bionest
“Beyond the Pill,” Part One: Value-Added Services Increasingly Needed Due to Changing Nature of Therapies
The notion of patient-centricity has gained increasing attention from drug developers and others in recent years, mostly in the area of chronic diseases and those requiring complex therapies. But value-added services, which go beyond simple initiatives addressed to patient compliance and access to therapy, are also gaining increasing attention from a variety of other audiences,...
23
Mar
2016
Bionest
Launch or License: Some Points to Consider, When You’re Considering Your First European Launch
For many young biotech and pharma companies, the decision about how to take their first drug to Europe has been simple: just license the European marketing rights to a company that already is well established there, and collect milestone payments and a stream of royalties. For an inexperienced company, dealing with the European regulatory and...
16
Mar
2016
Bionest
Making a “Moonshot” Against Cancer
President Obama, in his 2016 State of the Union Address, called on Vice President Biden to lead a new national “Moonshot” to “eliminate cancer as we know it.” The White House has since announced a billion dollar initiative — inspired by recent successes in the areas of cancer immunotherapy and multi-drug combinations — to jump-start this...
24
Feb
2016
Bionest
Orphan Drug Franchises Best Left to Mature Alone
Commercial success in the rare disease field depends on a highly patient-centric approach that connects effectively with rare disease patient communities at a senior management level and focuses on access and interactions with thought leaders and physicians, rather than on selling drug features and benefits. This is the topic of our latest contributed article for...
21
Jan
2016
Bionest
Increasing Role for Biomarkers in R&D, Clinical Medicine, and Pharma Marketing
Bionest team member Rachel Laing recently contributed to a feature in the January issue of PharmaVoice on the growing role and prominence of biomarker strategies in drug development and commercialization. In addition to helping to better identify those patients who will respond to a particular therapy, a biomarker strategy enables companies to differentiate their product and...
15
Dec
2015